GLAXF - Vir Bio COVID-19 Updates And Other News: The Good Bad And Ugly Of Biopharma
Vir Bio Moves Ahead with COVID Projects, Reports Higher Q1 Revenue
Vir Biotechnology (VIR) provided an update about its COVID projects, while confirming GlaxoSmithKline's (GSK) investment worth $250 million. The company is currently working on multiple clinical programs to address COVID 19 breakout. During the first quarter, Vir also inked several manufacturing agreements for producing antibodies for its clinical programs. The company stock is currently trading nearly 150 percent up on Year to Day basis.
Vir reported its first quarter revenue at $5.7 million, up from $3.7 million it had reported